Allscripts is collaborating with Microsoft to match patients with clinical trials.
Under a deal announced this week, Microsoft and Veradigm, Allscripts’ payer and life sciences division, will integrate research at the point of care through cloud-based electronic health record platforms, starting with those operated by Allscripts, a Chicago-based health information technology company.
The effort aims to more quickly bring new therapies to market and cut the cost of research and development by connecting patients, providers, researchers and study sponsors through electronic health record platforms, Stephanie Reisinger, Veradigm’s vice president and general manager of life sciences, said in an email.
Financial terms of the deal were not disclosed.
The timing is right, according to an Allscripts statement that references the U.S. Food & Drug Administration’s July 2018 guidance encouraging the use of electronic health record data in clinical investigations.
“New technologies and models have the potential to drastically improve the clinical research process,” Chris Sakalosky, vice president of U.S. health and life sciences at Microsoft, said in the statement. “Working alongside industry leaders like Veradigm, we believe solutions powered by Microsoft Azure and (artificial intelligence) will help biopharmaceutical and clinical research organizations better conduct research, and, in the future, improve quality of life.”
This isn’t the first time Allscripts and Microsoft have teamed up. The companies last year debuted Avenel, an electronic health record built using the MicrosoftAzure cloud that functions more like an app than a traditional electronic health record platform.